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Abstract
Background: Three* human polyomaviruses have been discovered recently, KIPyV, WUPyV and MCPyV. These
viruses appear to circulate ubiquitously; however, their clinical significance beyond Merkel cell carcinoma is almost
completely unknown. In particular, nothing is known about their preponderance in vertical transmission. The aim
of this study was to investigate the frequency of fetal infections by these viruses. We sought the three by PCR, and
MCPyV also by real-time quantitative PCR (qPCR), from 535 fetal autopsy samples (heart, liver, placenta) from
intrauterine fetal deaths (IUFDs) (N = 169), miscarriages (120) or induced abortions (246). We also measured the
MCPyV IgG antibodies in the corresponding maternal sera (N = 462) mostly from the first trimester.
Results: No sample showed KIPyV or WUPyV DNA. Interestingly, one placenta was reproducibly PCR positive for
MCPyV. Among the 462 corresponding pregnant women, 212 (45.9%) were MCPyV IgG seropositive.
Conclusions: Our data suggest that none of the three emerging polyomaviruses often cause miscarriages or
IUFDs, nor are they transmitted to fetuses. Yet, more than half the expectant mothers were susceptible to infection
by the MCPyV.
Background
Among the five* human polymaviruses known, aside
from the BK virus (BKV) and JC virus (JCV) [1,2],
three* new ones, KI polyomavirus (KIPyV), WU polyo-
mavirus (WUPyV), and Merkel cell polyomavirus
(MCPyV) have been discovered during the past few
years by use of advanced molecular techniques [3-5]. In
their DNA sequences, KIPyV and WUPyV are interre-
lated more than MCPyV, which differs from all the
human polyomaviruses known [6]. The KIPyV and
WUPyV were discovered in nasopharyngeal aspirates
(NPA) from children with respiratory tract infections
[3,4]. Although many reports have confirmed their pre-
sence in the upper airways of patients with respiratory
illness, evidence is lacking of their pathogenicity in this
context [7-10,12]. For these viruses, their tropism and
clinical significance are unknown. Likewise, for the
tumorigenic MCPyV [5], also found in the nasopharynx
[13-15], the mode of transmission and, host cells, as
well as latency characteristics are yet to be established.
MCPyV DNA has been detected in a variety of speci-
men types including skin, saliva, gut, and respiratory
secretion samples [5,16,17]. Recovery of complete
MCPyV genomes from the skin of 40% of healthy adults
and PCR detection of MCPyV in the skin of almost all
adults by cutaneous swabbing suggests that most adults
are persistently infected with this polyomavirus [18].
Another recent study revealed the viral DNA in environ-
mental samples (sewage and river water) [19], confirm-
ing that MCPyV indeed is a ubiquitous virus.
Serological studies have shown that initial exposure
to KIPyV and WUPyV, as well as MCPyV occurs often
in childhood, similar to that for BKV and JCV, and
that MCPyV circulates widely in the human population
[20-24]. Although most adults have been exposed to
MCPyV, the exact site(s) of MCPyV infection remain
unclear. Vertical transmission of many human DNA
and RNA viruses is well established. However, for
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Polyomaviridae this mode of transmission is far from
clear. Transplacental transmission of BKV was first
suggested by detection of the virus DNA in fetal tis-
sues [25], while others obtained no evidence of vertical
transmission [26]. IgM studies of BKV and JCV in
cord blood samples showed no apparent association
with congenital infection [27,28].
These findings prompted us to investigate a sizeable
material of fetal autopsy samples (placenta, heart, liver)
for the presence of the three polyomaviruses in order
to determine whether these viruses give rise to fetal
infections. We also studied the corresponding maternal
sera for MCPyV IgG antibodies, by a newly established
virus like particle (VLP) - based IgG assay (Chen et al,
in revision).
Materials and methods
Clinical samples
The DNA studies were carried out using formalin-fixed,
paraffin-embedded (FFPE) tissues - placenta, heart, and
liver - after intrauterine fetal deaths (IUFDs, N = 169),
miscarriages (N = 120), or using as controls, specimens
from induced abortions (N = 246) performed exclusively
due to medical indications. From each fetus, 3 organs
(when available; placenta, heart, and liver) were initially
studied in pools, by PCR for the three polyomaviruses
(KI, WU, and MC). In the positive pool its constituent
tissues (placenta and heart) were then re-examined
separately. Thus, a total of 535 fetuses were included in
the overall cohort. The sampling in the Helsinki region
occurred from July 1992 to December 1995 and January
2003 to December 2005 [29]. The gestational weeks of
the fetal deaths ranged from 11 to 42. In this study,
IUFD corresponds to fetal loss having occurred during
or after the 22nd gestational week, and miscarriage to
fetal loss having occurred earlier. Our number of IUFDs
represents 58% of all occurring in Helsinki during the
study period.
We furthermore examined for the presence of
MCPyV IgG antibodies all serum samples available
from the corresponding mothers (n = 462). These sam-
ples had been collected at the municipal maternity
centers during antenatal screening around the 9th
gestational week (mean 9; median 9; range 2 to 36)
and were stored frozen at the Finnish Maternity
Cohort, National Institute for Health and Welfare,
Oulu, Finland. The mothers’ ages ranged between 18
and 45 years (mean 31, median 31).
The study was approved by the Coordinating Ethics
Committee of the Hospital District of Helsinki and
Uusimaa. Permission for use of fetal tissues was
obtained from the National Supervisory Authority for
Welfare and Health (Valvira).
DNA preparation and PCRs
The paraffin blocks were punch-biopsied, proteinase
K-digested, and the DNA was prepared by salting out,
as described [29]. Briefly, tissue lysates were heated at
95°C for 10 min. The paraffin then appeared floating on
the surface, after centrifugation at 13,200 rpm for 5 min-
utes (Eppendorf; 4°C). Sodium chloride was added to
achieve a final concentration of 1.2 mol/L, and the sam-
ple was mixed for 20 s and recentrifuged. The superna-
tant was transferred to a new tube, carefully avoiding
particles. The DNA in the supernatant was precipitated
with absolute ethanol and was redissolved in 60 mL of
water. The DNA solution diluted 1 to 10 was stored at -
20°C until use. Water, as a negative control, was
inserted between every 20 samples and was prepared
along with the tissue pools.
All these DNA preparations were b -globin-PCR-posi-
tive, pointing to DNA stability and lack of appreciable
PCR inhibition. The WUPyV and KIPyV nested PCRs
employed primer set A (table 1) [12]. For MCPyV DNA
detection by qualitative PCRs, two primer sets were
used (table 1); all samples were first studied by the LT3
nested PCR [15], and were reanalyzed by the LT1/M1
nested PCR [30], and samples with positive results by
agarose gel electrophoresis were DNA sequenced. As
short PCR products ought to be used when working
with FFPE tissues [31,32] we reanalyzed all pools with a
real-time quantitative PCR with an amplicon length of
59 bp, as described [13].
PCR sensitivity
For detection of KIPyV/WUPyV and MCPyV we per-
formed a highly sensitive PCR assay [15]. As positive
controls and to determine assay sensitivities by limiting
dilution analysis, plasmids containing the VP2 gene of
WUPyV (EU693907) and KIPyV (EU358767) and the
LT3 amplification product of MCPyV (EU375803) were
constructed; the amplification products of the VP2
genes were cloned into pCR8/GW/TOPO (Invitrogen;
Carlsbad, CA, USA) whereas the MCPyV LT3 region
was synthesized and cloned into pGOv4 by Gene Ora-
cle, Inc. (San Leandro, USA). In the MCPyV and
KIPyV/WUPyV assays, plasmid controls with 30 and 5
copies/reaction were reproducibly positive, respectively.
Of note, the sensitivities were unaffected by the inclu-
sion of genomic human DNA from cultured 293T cells
at 100 ng per reaction (4 ng/μl). In non-nested format
with 40 PCR cycles the LT3 primers had a sensitivity 1
log lower than that of the nested assay both in the pre-
sence and absence of human genomic DNA. In addition,
we also used a previously established real time quantita-
tive PCR for MCPyV, where a plasmid control with 2
copies/reaction was reproducibly positive [13].
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Sequence analyses
The MCPyV PCR products were purified for automated
sequencing using the High Pure PCR product purifica-
tion kit (Roche). The resulting DNA sequences using
BLAST were aligned against the reference sequences in
GenBank including accession numbers of [gb|
EU375803.1]; [gb|EU375804.1]; [gb|FJ173815.1]; [gb|
FJ464337.1]; [gb|HM011538] and [gb|HM011557].
MCPyV antibody EIA
MCPyV IgG antibodies were measured by EIA based on
virus protein 1 (VP1) VLPs (Chen et al, in revision).
Briefly, the VP1-VLPs expressed in insect cells and
purified by CsCl density gradient centrifugation were
biotinylated and attached (at 60 ng/well) to streptavidin-
coated microtiter plates (Thermo Scientific) and
saturated with a sample diluent (Ani Labsystems). The
sera (1:200) were applied in duplicate, the bound IgG
were quantified with peroxidase-conjugated anti-human
IgG (1:2000; DakoCytomation) using H2O2 and OPD
substrates, and the absorbances at 492 nm were read
after blank subtraction. The EIA cut-off for IgG positiv-
ity is 0.120 OD units.
Results and Discussion
Among the 535 fetal autopsy samples studied in pools,
none was PCR positive for KIPyV or WUPyV DNA. On
the other hand, one pool was positive for MCPyV by
the LT3 PCR. Tissue samples from 2 sites were available
for further study of this fetus. On retesting of the pla-
centa and fetal heart separately, the heart was PCR
negative and the placenta was positive for MCPyV.
However, it was negative by the LT1/M1 PCR for
MCPyV. DNA preparations re-extracted from the other
half of the same punch biopsy, as well as those obtained
via another punch from the same paraffin block, showed
exactly the same MCPyV DNA results. Furthermore, we
studied all samples with a real-time qPCR for MCPyV
of a different genomic region, with an identical result;
the placenta was positive with a Ct value of 38.4, while
the biopsy from the fetal heart was negative. To verify
the specificity of the amplified products and to detect
possible genomic variants, the MCPyV LT3 PCR pro-
ducts were sequenced. They showed 100% homology
with all the existing database sequences. N.B., the mis-
carried fetus, with gastroschisis and umbilical cord com-
plications, was deceased in 1994, in gestational week 17.
In addition, we examined for circulating MCPyV IgG
antibodies the corresponding pregnant women. Of the
462 maternal sera, 45.9% (212) showed positive results.
We searched formalin-fixed, paraffin-embedded tissues
- placenta, heart, and liver - of 535 fetal autopsy samples
for the KI, WU, and MC polyomaviruses. We found no
genomic DNAs of KIPyV or WUPyV in any of the still-
born or deceased fetuses. This suggests that during the
study period neither of these two newly found viruses (i)
often caused miscarriages or IUFDs, (ii) nor were inci-
dentally (as bystanders) transmitted to remain in the
fetuses succumbing for other reasons. Whether the
exclusive mechanism in our mid-size series was the ser-
endipitous absence of maternal infections (primary; sec-
ondary) caused by these viruses, or pathogenetic
resistance by other mechanisms, remains to be shown.
On the other hand, it was interesting to observe LT3
PCR and VP1 qPCR positivity for MCPyV (reproducibly,
and of correct DNA sequence) in the placenta of one
miscarriage in the 17th gestational week. The negativity
of this placenta with the other MCPyV PCR (LT1/M1)
may be due to the known sensitivity difference of the
PCR assays [15,30].
As for the previously known human polyomaviruses
BKV and JCV, no fetal autopsy materials have been
found positive for JCV DNA, whereas one study [25]
reported a high genoprevalence of BKV DNA; BKV ver-
tical transmission has been denied by others [11,33,34],
however.
Ours is to our knowledge the first study in which fetal
tissues have been searched for the newly discovered
Table 1 Primers and probe used to detect KIPyV, WUPy and MCPyV
PCR and Virus Primer Sequence 5 ® 3 Region Amplicon size
Forward Reverse
Nested PCR outer primers
KIPyV, WUPyV ATCTRTAGCTGGAGGAGCAGAG CCYTGGGGATTGTATCCTGMGG VP2 336 bp
MCPyV (LT3) TTGTCTCGCCAGCATTGTAG ATATAGGGGCCTCGTCAACC LT 309 bp
MCPyV (LT1) TACAAGCACTCCACCAAAGC TCCAATTACAGCTGGCCTCT LT 440 bp
Nested PCR inner primers
KIPyV, WUPyV RTCAATTGCTGGWTCTGGAGCTGC TCCACTTGSACTTCCTGTTGGG VP2 277 bp
MCPyV (LT3) TGACGTGGGGAGAGTGTTTTTG GAGGAAGGAAGTAGGAGTCTAGAAAAG LT 155 bp
MCPyV (M1) GGCATGCCTGTGAATTAGGA TTGCAGTAATTTGTAAGGGGACT LT 179 bp
MCPyV qPCR primers TGCCTCCCACATCTGCAAT GTGTCTCTGCCAATGCTAAATGA VP1 59 bp
MCPyV probe FAM-TGTCACAGGTAATATC-MGBNFQ
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human polyomaviruses. Serology has shown that a high
proportion of adults have been exposed to MCPyV, and
that the infection can be acquired early in life [20-24].
We detected an IgG seroprevalence for MCPyV of
45.9% among the pregnant women. This value is in line
with previous reports and shows that more than half
our women were susceptible to MCPyV infection. Tol-
stov et al. studying serologically 6 children 1 year or
younger found no evidence of MCPyV vertical transmis-
sion [24].
Conclusions
While the three* emerging polyomaviruses occur fre-
quently in tissues of many different types, and MCPyV
also in environmental samples [3,4,13,15,18,35], our
PCR data from 535 pregnancies suggest that none of
these viruses are frequently transmitted vertically.
Further studies with larger populations may, however,
be warranted to determine which role, if any, MCPyV
plays in pregnant women and their offspring.
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